drugset
Drugs / monosialotetrahexosylganglioside Sodium
last change May 2026 re-read 3 minutes ago

monosialotetrahexosylganglioside Sodium

also known as monosialotetrahexosylganglioside · GM1 · shenjie · Sygen
Developed for
chemotherapy-induced neuropathy · cognitive disorder · gastric cancer · ischemic stroke · toxic polyneuropathy
Investigated by
Tianjin Medical University Cancer Institute and Hospital · Sun Yat-sen University · Alliance for Clinical Trials in Oncology · National Cancer Institute (NCI) · Xuanwu Hospital, Beijing

Trials 7

today NCT07519044 · Ph 4 NCT05751668 · Ph 2 NCT04395339 · Ph 3 NCT02486198 · Ph 3 NCT02093910 · Ph 2 NCT02024438 · Ph 3 NCT02024412 · Ph 3
201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 22 trials
Phase 2 NCT05751668 Nov 2023 → Mar 2028 chemotherapy-induced neuropathy, female breast carcinoma Alliance for Clinical Trials in Oncology Suspended No outcome recorded
Phase 2 NCT02093910 Apr 2014 → Apr 2017 plasma cell myeloma Sun Yat-sen University Unknown No outcome recorded
Phase 34 trials · 1 met primary
Phase 3 NCT04395339 May 2020 → Jul 2024 GM1 gangliosidosis, breast cancer, cognitive disorder, metastatic malignant neoplasm in the brain Sun Yat-sen University Terminated No outcome recorded Stop: Enrollment
Phase 3 NCT02486198 May 2015 → Jan 2018 toxic polyneuropathy Tianjin Medical University Cancer Institute and Hospital Completed Met primary
Phase 3 NCT02024438 Dec 2013 → Dec 2016 gastric cancer Tianjin Medical University Cancer Institute and Hospital Unknown No outcome recorded
Phase 3 NCT02024412 Nov 2013 → Dec 2016 colorectal cancer Tianjin Medical University Cancer Institute and Hospital Unknown No outcome recorded
Phase 41 trial
Phase 4 NCT07519044 May 2026 → Jan 2027 expected ischemic stroke Xuanwu Hospital, Beijing Recruiting No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as monosialotetrahexosylganglioside Sodium ClinicalTrials.gov intervention name — accepted as the source's own label NCT02024412 ↗
1

NCT02024438 ↗
Known as GM1 “Monosialotetrahexosylganglioside (GM1) is a unique glycosphingolipid that crosses the blood-brain barrier to provide neuroprotection by suppressing oxidative stress,...” NCT07519044 ↗
2

“We conducted a randomised controlled trial to investigate the efficacy of monosialotetrahexosylganglioside (GM1) in treating chronic OIPN.” PMID 34765950 ↗ Oct 2021

“Monosialotetrahexosyl ganglioside (GM1)” NCT04395339 ↗
Known as monosialotetrahexosylganglioside “Monosialotetrahexosylganglioside (GM1) is a unique glycosphingolipid that crosses the blood-brain barrier to provide neuroprotection by suppressing oxidative stress,...” NCT07519044 ↗
4

“We conducted a randomised controlled trial to investigate the efficacy of monosialotetrahexosylganglioside (GM1) in treating chronic OIPN.” PMID 34765950 ↗ Oct 2021

NCT02093910 ↗

NCT04395339 ↗

NCT05751668 ↗
Known as shenjie “it is a component extract from pig's brain,shenjie is the brand name” NCT02024412 ↗
Known as Sygen ChEMBL registry synonym — accepted as the source's own label CHEMBL5095280 ↗
Route Intravenous “monosialotetrahexosylganglioside was used at the dosage of 100mg/d intravenously at d1-2,8-9,15-16,22-23 every cycle.” NCT02093910 ↗